Literature DB >> 11046034

Functional defects of NK cells treated with chloroquine mimic the lytic defects observed in perforin-deficient mice.

M Austin Taylor1, M Bennett, V Kumar, J D Schatzle.   

Abstract

NK cells are the primary effectors mediating acute rejection of incompatible bone marrow cell grafts. To reduce rejection, we evaluated the ability of chloroquine (CHQ) to prevent perforin-dependent NK cell activity. Perforin is a key cytotoxic component released from the lytic granules of activated NK cells. Generation of functional perforin requires an acidic protease activity that occurs in the secretory, lytic lysosomes. Our hypothesis was that CHQ, a lysosomotropic reagent, would raise the pH of the acidic compartment in which perforin is processed and thereby block perforin maturation and cytotoxicity. We have measured NK cytotoxicity in vivo by clearance of YAC-1 tumor cells from the lungs and by rejection of incompatible bone marrow transplants and in vitro by cytolysis of YAC-1 and Jurkat cells. The engraftment of bone marrow cells was monitored by recolonization of the spleen with hemopoietic cells from transplants of MHC class I-deficient bone marrow cells into lethally irradiated recipient mice. Transplant rejection was compared in two inbred strains of mice: 129, which apparently use perforin-dependent cytotoxicity, and C57BL/6, in which rejection can be perforin-independent. CHQ treatment reduced NK cell activity in 129 mice in which perforin is important for mediating rejection. CHQ affected the fraction of NK cell cytolysis that was Fas independent. In addition, we found that CHQ prevents perforin processing by LAK cells in vitro. These data indicate that CHQ may impair rejection of incompatible bone marrow transplants and other functions mediated by NK and cytotoxic T cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046034     DOI: 10.4049/jimmunol.165.9.5048

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Stepwise cytoskeletal polarization as a series of checkpoints in innate but not adaptive cytolytic killing.

Authors:  Christoph Wulfing; Bozidar Purtic; Jennifer Klem; John D Schatzle
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-11       Impact factor: 11.205

2.  Transience in polarization of cytolytic effectors is required for efficient killing and controlled by Cdc42.

Authors:  Parisa Sinai; Chau Nguyen; John D Schatzle; Christoph Wülfing
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

Review 3.  Are circadian rhythms the code of hypothalamic-immune communication? Insights from natural killer cells.

Authors:  Alvaro Arjona; Dipak K Sarkar
Journal:  Neurochem Res       Date:  2007-10-27       Impact factor: 3.996

4.  Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells.

Authors:  Jiao Wang; Sandra Toregrosa-Allen; Bennett D Elzey; Sagar Utturkar; Nadia Atallah Lanman; Victor Bernal-Crespo; Matthew M Behymer; Gregory T Knipp; Yeonhee Yun; Michael C Veronesi; Anthony L Sinn; Karen E Pollok; Randy R Brutkiewicz; Kathryn S Nevel; Sandro Matosevic
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-09       Impact factor: 12.779

5.  Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease.

Authors:  A Di Sabatino; R Ciccocioppo; F Cupelli; B Cinque; D Millimaggi; M M Clarkson; M Paulli; M G Cifone; G R Corazza
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

6.  CpG-ODN enhances ingestion of apoptotic neutrophils by macrophages.

Authors:  Jiong Wang; Wei-Lin Huang; Rong-Yu Liu
Journal:  Clin Exp Med       Date:  2008-10-25       Impact factor: 3.984

Review 7.  Rethinking the role of hydroxychloroquine in the treatment of COVID-19.

Authors:  Eric A Meyerowitz; Augustin G L Vannier; Morgan G N Friesen; Sara Schoenfeld; Jeffrey A Gelfand; Michael V Callahan; Arthur Y Kim; Patrick M Reeves; Mark C Poznansky
Journal:  FASEB J       Date:  2020-04-29       Impact factor: 5.191

Review 8.  SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.

Authors:  Rajkumar Singh Kalra; Dhanendra Tomar; Avtar Singh Meena; Ramesh Kandimalla
Journal:  Pathogens       Date:  2020-07-07

Review 9.  COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.

Authors:  Hussain Ahmed Raza; Javeria Tariq; Vikas Agarwal; Latika Gupta
Journal:  Rheumatol Int       Date:  2021-01-01       Impact factor: 2.631

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.